Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 9/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL1683285 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13575802 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13318941 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13743095 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13198584 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14430952 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL23936980 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14430866 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL2305070 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14621551 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956602-B2 | Delivery of drugs | Landec, Inc. (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| US-8524259-B2 | Systems and methods for delivery of materials | LANDEC CORPORATION (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130095160-A1 | RESORBABLE POLYSTATIN BIOMATERIALS | REGRANION, LLC | 2013-04-18 | — | — | US | disclosed |
| US-8399007-B2 | Method for formulating a controlled-release pharmaceutical formulation | LANDEC CORPORATION (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2502619-A2 | Systems and methods for delivery of materials | Landec Corporation (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2500015-A1 | Delivery of drugs | Landec Corporation (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2229150-B1 | SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS | LANDEC CORP (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1782804-B1 | MEDICINAL COMPOSITION, COMPRISING A HMG-CoA REDUCTASE INHIBITOR AND AN AMINO ALCOHOL DERIVATIVE, AS IMMUNOSUPPRESSANT | DAIICHI SANKYO CO LTD (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20110009571-A1 | SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS | ALCON RESEARCH, LLC | 2011-01-13 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | SANKYO COMPANY, LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | SANKYO COMPANY, LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1782804-A1 | MEDICINAL COMPOSITION AS IMMUNOSUPPRESSANT | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2005019155-A1 | PROCESS FOR THE PREPARATION OF 1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (BETA R,DELTA R,1S,2S,6S,8S,8AR)-1-NAPHTHALENEHEPTANOIC ACID, SODIUM SALT. | BIOCON LIMITED (IN) | 2005-03-03 | — | — | WO | disclosed |
| EP-1242051-A4 | NOVEL FORMS OF PRAVASTATIN SODIUM | BIOGAL GYOGYSZERGYAR (HU) | 2004-05-12 | — | — | EP | disclosed |
| EP-1242051-A1 | NOVEL FORMS OF PRAVASTATIN SODIUM | BIOGAL GYOGYSZERGYAR RT. (HU) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001043723-A1 | NOVEL FORMS OF PRAVASTATIN SODIUM | BIOGAL GYOGYSZERGYAR RT. (HU) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095160-A1 | RESORBABLE POLYSTATIN BIOMATERIALS | LCP1, CD68, CROCC | HMGCR 1549/4885SLCO1B1 4690/4885SLC22A8 4669/4885 |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | HMGCR, SHMT1, CYP11B1 | HMGCR 1/4885SLCO1B1 629/4885SLC22A8 908/4885 |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | HMGCR 29/4885SLCO1B1 3052/4885SLC22A8 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.